[A20-09] Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Last updated 04.05.2020

Project no.:

Commission awarded on 03.02.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


Adults with type 2 diabetes mellitus; monotherapy for patients in whom diet and exercise alone do not provide sufficient glycaemic control and for whom metformin is considered inappropriate due to intolerance or contraindications; combination therapy for patients in whom diet and exercise and the treatment with other blood-glucose lowering drugs do not provide sufficient glycaemic control

Result of dossier assessment:

Combination therapy for patients in whom diet and exercise and treatment with short-acting insulin (with or without another blood-glucose lowering drug) do not provide sufficient glycaemic control: hint of considerable added benefit if the treatment goal is a not near-normal blood glucose level. All other therapeutic indications and goals: added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.